Cyclerion Therapeutics
CYCN
34 hedge funds and large institutions have $8.95M invested in Cyclerion Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 8 closing their positions.
14,700% more call options, than puts
Call options by funds: $148K | Put options by funds: $1K
0.02% less ownership
Funds ownership: 2.39% → 2.37% (-0.02%)
15% less funds holding
Funds holding: 40 → 34 (-6)
35% less capital invested
Capital invested by funds: $13.7M → $8.95M (-$4.72M)
55% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 11
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$185K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$16.5K |
| 3 |
PIM
Penobscot Investment Management
Boston,
Massachusetts
|
+$6.31K |
| 4 |
Morgan Stanley
New York
|
+$5.53K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.47K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$61.1K |
| 2 |
VF
Virtu Financial
New York
|
-$32K |
| 3 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$19.4K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$19.3K |
| 5 |
Jane Street
New York
|
-$16.7K |
CYCN Hedge Fund Activity: Q1 2023 in Review
34 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q1 2023, worth a combined $8.95M — down 35% from $13.7M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CYCN and 3 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 5 added.
The largest buyer was CAPTRUST Financial Advisors, opening a new position worth an estimated $185K. The largest seller was Renaissance Technologies, cutting an estimated $61.1K.
- 34 institutional investors held Cyclerion Therapeutics (CYCN) as of Q1 2023, down from 40 in Q4 2022.
- Funds reported $8.95M of Cyclerion Therapeutics stock for Q1 2023, down 35% quarter-over-quarter.
- 3 funds opened new Cyclerion Therapeutics positions in Q1 2023 and 8 closed out, a net change of -5 holders.
- The largest Cyclerion Therapeutics buyer in Q1 2023 was CAPTRUST Financial Advisors, an estimated $185K added.
- The largest Cyclerion Therapeutics seller in Q1 2023 was Renaissance Technologies, an estimated $61.1K sold.
Based on aggregated 13F filings for Q1 2023.